Published in Cancer Metastasis Rev on March 01, 2011
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res (2012) 3.07
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol (2013) 1.31
The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci (2013) 1.28
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One (2011) 1.08
Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron (2012) 1.03
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother (2013) 0.94
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunol Res (2016) 0.90
Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients. BMC Cancer (2016) 0.83
The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore. Oncotarget (2015) 0.82
Inflammation in uveal melanoma. Eye (Lond) (2012) 0.81
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 0.81
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80
MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. Oncotarget (2016) 0.80
NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses. Hum Vaccin Immunother (2013) 0.79
Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced non-small-cell lung cancer. J Cancer Res Clin Oncol (2013) 0.79
Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword. PPAR Res (2012) 0.77
Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy. Front Oncol (2012) 0.76
Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. Curr Colorectal Cancer Rep (2015) 0.76
Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron (2014) 0.75
Prognostic potential of an immune score based on the density of CD8(+) T cells, CD20(+) B cells, and CD33(+)/p-STAT1(+) double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients. Chin J Cancer Res (2016) 0.75
Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model. EJNMMI Res (2015) 0.75
The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. Ann Transl Med (2016) 0.75
Metastatic melanoma cells evade immune detection by silencing STAT1. Int J Mol Sci (2015) 0.75
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Sci Rep (2016) 0.75
Do inflammatory markers predict prognosis in patients with synchronous colorectal cancer? Medicine (Baltimore) (2017) 0.75
Cytotoxic T-cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998) 6.42
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63
Cancer immunology. N Engl J Med (2008) 5.22
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
Colorectal cancer. Lancet (2005) 4.90
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
A phosphatase associated with metastasis of colorectal cancer. Science (2001) 3.86
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res (2001) 3.23
Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer (1995) 2.82
Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol (1986) 2.80
Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 2.37
The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res (2007) 2.34
Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med (2007) 2.29
Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene (2004) 2.09
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology (2009) 2.01
An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res (2002) 1.82
PRL-3 expression in metastatic cancers. Clin Cancer Res (2003) 1.73
TLR7 and TLR8 as targets in cancer therapy. Oncogene (2008) 1.72
Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69
Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J Clin Pathol (1989) 1.64
Colorectal cancer: genetics of development and metastasis. J Gastroenterol (2006) 1.63
Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol (2003) 1.61
Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol (2005) 1.58
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology (2005) 1.56
Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta (2006) 1.53
Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med (2003) 1.53
Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer (1984) 1.52
Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res (2009) 1.51
Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther (2007) 1.50
Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer (2005) 1.46
Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Res (2001) 1.40
Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer (1999) 1.40
Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol (2004) 1.26
The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun (2009) 1.14
Colon cancer prognosis prediction by gene expression profiling. Oncogene (2005) 1.13
Survival and the immune response in patients with carcinoma of the colorectum. Gut (1979) 1.12
Biology of colorectal liver metastases: A review. J Surg Oncol (2006) 1.11
Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther (2008) 1.04
Spontaneous regression of thoracic malignancies. Respir Med (2010) 1.04
Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. J Surg Res (2005) 0.97
Osteopontin identified as colon cancer tumor progression marker. C R Biol (2004) 0.96
Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res (2005) 0.94
Gene expression profiling in lymph node-positive and lymph node-negative colorectal cancer. Dis Colon Rectum (2004) 0.94
Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol (2009) 0.89
Dormancy in a model of murine B cell lymphoma. Semin Cancer Biol (2001) 0.89
T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol (1999) 0.88
Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes. Anticancer Res (2009) 0.88
Involvement of cyclin D3 in liver metastasis of colorectal cancer, revealed by genome-wide copy-number analysis. Lab Invest (2005) 0.87
Generation of experimental allergic airways inflammation in the absence of draining lymph nodes. J Clin Invest (2001) 0.84
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 2.37
The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res (2007) 2.34
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology (2009) 2.01
CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics (2013) 1.82
Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol (2013) 1.55
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol (2015) 1.35
Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol (2011) 1.32
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res (2014) 1.29
The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol (2008) 1.25
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med (2014) 1.21
iLAP: a workflow-driven software for experimental protocol development, data acquisition and analysis. BMC Bioinformatics (2009) 1.14
Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha. J Immunol (2002) 1.14
Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol (2011) 1.09
Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med (2012) 1.04
The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron (2012) 0.98
Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci U S A (2006) 0.97
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96
Immunosurveillance in human non-viral cancers. Curr Opin Immunol (2011) 0.95
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95
IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer (2003) 0.87
Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. J Clin Invest (2002) 0.82
Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood (2004) 0.80
Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. Pharmacol Ther (2010) 0.79
A new platform linking chromosomal and sequence information. Chromosome Res (2007) 0.78
Memory T-cell responses and survival in human cancer: remember to stay alive. Adv Exp Med Biol (2010) 0.78
The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol (2011) 0.78
Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. BMC Genomics (2010) 0.76
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell (2016) 0.76